SCNX SCNX
Company Profile ↓Company Overview
SCNX (SCNX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $431.61K (+215.9% YoY); net profit $-41.51M.
- Trailing 12 Months Year-on-year growth — revenue +215.9%, earnings -557.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -6.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.41% |
| 1 Year: | 215.87% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -557.90% |
Stock Price Performance
| 1 Year: | -79.95% |
| 6 Months: | -14.88% |
| 3 Months: | -0.51% |
| 1 Month: | +12.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -6.4% CAGR over 5 years.
- Trading 85.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 837.69K | 847.47K | 1.51M | 1.92M | 2.31M | 2.20M | 6.59M | 6.33M | 3.05M | 1.90M | 2.55M | 3.24M | 3.28M | 2.06M | 493.32K | 366.53K | 392.29K | - | 18.70K | 64.86K | 10.26K | - | 590.05K | 56.33K |
| Gross Profit | 132.34K | -45.27K | 97.41K | 236.53K | 295.54K | 465.67K | 785.19K | 937.24K | 628.92K | 587.73K | 610.83K | 745.94K | 704.73K | 735.87K | 852.92K | 837.69K | 845.13K | 1.15M | 1.16M | 1.31M | 1.64M | 2.00M | 1.93M | 1.38M | 841.39K | 1.28M | 1.34M | 1.17M | 1.37M | 73.22K | 67.14K | 39.59K | - | -703 | 3.88K | 673 | - | 574.62K | 53.85K |
| Operating Income | -183.93K | -282.83K | -344.52K | -300.03K | -349.83K | -442.65K | -26.45K | -76.56K | -130.28K | -577.58K | -245.22K | 141.45K | 48.78K | 89.61K | 98.73K | 31.45K | 91.83K | 171.76K | 132.71K | 177.85K | 188.23K | -535.28K | 145.82K | -644.25K | -2.57M | -1.30M | -968.57K | -1.10M | -218.76K | -806.09K | -599.78K | -761.68K | -5.49M | -1.50M | -3.50M | -3.57M | -5.16M | -4.36M | -3.51M |
| Net Income | -184.50K | -283.68K | -922.00K | -301.02K | -351.88K | -443.62K | -54.36K | -123.76K | -372.38K | -1.10M | -842.88K | 79.73K | -6.84K | 76.19K | 82.27K | 20.51K | 94.25K | 125.23K | 57.98K | 27.57K | 180.30K | -542.59K | 138.39K | -651.52K | -2.58M | -1.30M | -965.84K | -1.11M | -503.00K | -677.95K | -1.97M | -3.53M | 21.25M | -1.83M | -3.18M | -3.06M | -6.72M | -3.61M | -3.40M |
| Diluted EPS | 0.00 | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.04 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.02 | -0.07 | 0.02 | -0.08 | -0.32 | -0.16 | -0.12 | -1.99 | -0.91 | -1.01 | -2.90 | -4.57 | 16.77 | -1.30 | -1.34 | -0.33 | -0.48 | -0.19 | -0.08 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25M | 574.68K | 843.55K | 169.34K | 793.98K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 955.88K | 1.50M | 2.91M | 2.48M | 2.93M | 3.83M | 7.44M | 17.12M | 9.89M | 10.25M | 1.36M | 136.64K | 431.61K |
| Gross Profit | 11.81K | 1.06M | 2.72M | 2.48M | 2.93M | 3.38M | 4.87M | 5.71M | 4.75M | 5.52M | 49.03K | 6.00K | 331.48K |
| Operating Income | -2.08M | -1.43M | -137.07K | -1.01M | 395.10K | -87.62K | 125.22K | -2.51M | -5.29M | -2.92M | -4.40M | -14.70M | -42.59M |
| Net Income | -2.09M | -2.01M | -1.12M | -2.76M | 288.98K | 9.04K | -284.43K | -2.54M | -5.32M | -3.47M | -17.84M | 9.07M | -41.51M |
| Diluted EPS | -0.15 | -0.07 | -0.04 | -0.09 | 0.01 | 0.00 | -0.05 | - | -0.65 | -6.13 | -23.35 | 2.48 | -2.70 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 2.24M | 1.96M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 403.87K | 1.22M | 2.03M | 337.12K | 617.48K | 2.23M | 5.57M | 9.79M | 5.77M | 3.71M | 12.53M | 104.85M | 84.18M |
| Total Equity | - | 130.87K | 668.44K | 267.02K | -1.15M | -311.93K | 844.67K | 4.14M | 8.68M | 3.77M | 763.14K | 542.35K | 79.07M | 70.12M |
| Cash & Equivalents | 3.38K | 84.32K | 695.82K | 78.71K | 14.68K | 183.91K | 869.56K | 2.87M | 5.92M | 3.12M | 1.09M | 151.91K | - | 6.66M |
| Long Term Debt | - | - | - | - | - | 666.52K | 522.05K | 225.00K | - | - | - | - | 2.90M | - |
| Total Liabilities | - | - | 553.68K | 1.76M | 1.49M | 929.41K | 1.38M | 1.43M | 1.11M | 2.00M | 3.37M | 11.99M | 25.78M | 14.06M |
| Current Liabilities | - | 273.00K | 553.68K | 1.76M | 1.47M | 525.36K | 860.37K | 520.82K | 842.24K | 926.03K | 2.15M | 11.56M | 7.91M | 2.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -844.58K | -1.06M | 90.39K | -503.53K | 171.67K | 273.39K | 141.78K | -2.21M | -2.57M | -1.53M | -2.23M | -14.27M | -13.38M |
| Investing Cash Flow | 10.99K | - | - | -78.00K | 0 | -265.28K | -332.25K | -37.51K | -22.60K | -427.85K | -275.72K | 27.55M | - |
| Financing Cash Flow | 936.51K | 1.69M | 1.36M | - | -2.44K | 677.54K | 2.19M | 5.30M | -208.18K | -35.17K | 1.41M | -12.98M | 19.73M |
| Capital Expenditure | -10.99K | - | - | - | - | - | - | -37.51K | -22.60K | - | - | -12.00K | - |
| Free Cash Flow | -855.57K | - | - | - | - | - | - | -2.25M | -2.59M | - | - | -14.28M | - |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | 14.86M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 1.2% | 70.6% | 93.5% | 100.0% | 100.0% | 88.3% | 65.5% | 33.3% | 48.0% | 53.8% | 3.6% | 4.4% | 76.8% |
| Operating Margin % | -218.0% | -95.7% | -4.7% | -40.6% | 13.5% | -2.3% | 1.7% | -14.6% | -53.5% | -28.4% | -322.4% | -10,758.7% | -9,867.9% |
| Net Margin % | -218.8% | -134.5% | -38.4% | -111.2% | 9.9% | 0.2% | -3.8% | -14.8% | -53.8% | -33.9% | -1,308.3% | 6,634.7% | -9,618.0% |
| ROE % | -1,598.0% | -301.0% | -418.4% | 240.4% | -92.6% | 1.1% | -6.9% | -29.2% | -141.0% | -455.0% | -3,290.0% | 11.5% | -59.2% |
| ROCE % | -1,592.5% | -214.2% | -51.3% | 88.6% | 428.9% | -6.4% | 2.5% | -28.0% | -109.3% | -186.5% | -450.2% | -15.2% | -52.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCNX
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli™ for increased prescription volume and revenue growth COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company fo…
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broadening commercial and Medicare supplemental…
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating c…
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians a…
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- SCIEN…
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians …
SCNX — Frequently Asked Questions
What is the current share price of SCNX?
As of 2026-08-05 17:25 PDT, SCNX trades at $0.39 on NASDAQ/NYSE. Its 52-week range is $0.24 to $2.60.
What is the P/E ratio of SCNX?
SCNX trades at a trailing price-to-earnings (P/E) ratio of -0.14.
What is the return on equity (ROE) of SCNX?
SCNX has a return on equity (ROE) of -59.20%. Its return on capital employed (ROCE) is -52.30%.
Is SCNX a good stock to buy?
This page provides a data-driven analysis of SCNX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.